Despite the controversies, many laboratories are currently working on the development of redox inhibitors of APE1, including a derivate of E3330, APX3330 which is now in phase II clinical trials for pancreatic cancer and hematopoietic malignancies (via personal communication). This evidence concerns the gene APEX1 and familial pancreatic carcinoma.